Tscan Therapeutics Stock Buy Hold or Sell Recommendation
| TCRX Stock | USD 1.74 0.05 2.79% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tscan Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Tscan Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Tscan Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Tscan Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide. In addition, we conduct extensive research on individual companies such as Tscan and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Tscan |
Execute Tscan Therapeutics Buy or Sell Advice
The Tscan recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tscan Therapeutics. Macroaxis does not own or have any residual interests in Tscan Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tscan Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Tscan Therapeutics Trading Alerts and Improvement Suggestions
| Tscan Therapeutics generated a negative expected return over the last 90 days | |
| Tscan Therapeutics may become a speculative penny stock | |
| Tscan Therapeutics has high historical volatility and very poor performance | |
| Tscan Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.82 M. Net Loss for the year was (127.5 M) with loss before overhead, payroll, taxes, and interest of (2.03 M). | |
| Tscan Therapeutics currently holds about 125.6 M in cash with (110.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tscan Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Baker Bros. Advisors Lp of 758094 shares of Tscan Therapeutics at 1.95 subject to Rule 16b-3 |
Tscan Therapeutics Returns Distribution Density
The distribution of Tscan Therapeutics' historical returns is an attempt to chart the uncertainty of Tscan Therapeutics' future price movements. The chart of the probability distribution of Tscan Therapeutics daily returns describes the distribution of returns around its average expected value. We use Tscan Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tscan Therapeutics returns is essential to provide solid investment advice for Tscan Therapeutics.
| Mean Return | -1.28 | Value At Risk | -7.51 | Potential Upside | 6.33 | Standard Deviation | 5.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tscan Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tscan Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Tscan Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Tscan Therapeutics back and forth among themselves.
| Shares | Abrdn Plc | 2024-12-31 | 883.7 K | State Street Corp | 2024-12-31 | 800.9 K | Dc Funds, Lp | 2024-12-31 | 630 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 412.9 K | Northern Trust Corp | 2024-12-31 | 322.1 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 280 K | Tocqueville Asset Management L.p. | 2024-12-31 | 260.9 K | Goldman Sachs Group Inc | 2024-12-31 | 160.7 K | Bank Of America Corp | 2024-12-31 | 150.1 K | Ecor1 Capital, Llc | 2024-12-31 | 5 M | Blackrock Inc | 2024-12-31 | 5 M |
Tscan Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (4.2M) | (9.9M) | (4.2M) | (64.0M) | (52.6M) | (50.0M) | |
| Change In Cash | (7.0M) | 131.1M | (41.4M) | 13.3M | 45.3M | 29.8M | |
| Free Cash Flow | (7.3M) | (58.6M) | (70.7M) | (64.5M) | (114.6M) | (108.9M) | |
| Depreciation | 1.2M | 3.3M | 5.1M | 5.4M | 4.1M | 3.6M | |
| Other Non Cash Items | 2K | 9.2M | 260K | (315K) | (2.0M) | (1.9M) | |
| Capital Expenditures | 4.2M | 9.9M | 4.2M | 3.1M | 3.8M | 4.9M | |
| Net Income | (26.1M) | (48.6M) | (66.2M) | (89.2M) | (127.5M) | (121.1M) | |
| End Period Cash Flow | 35.4M | 166.4M | 125.1M | 138.4M | 183.7M | 126.7M |
Tscan Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tscan Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tscan Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tscan stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.25 | |
β | Beta against Dow Jones | 0.31 | |
σ | Overall volatility | 3.89 | |
Ir | Information ratio | -0.23 |
Tscan Therapeutics Volatility Alert
Tscan Therapeutics exhibits very low volatility with skewness of -1.96 and kurtosis of 10.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tscan Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tscan Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tscan Therapeutics Fundamentals Vs Peers
Comparing Tscan Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tscan Therapeutics' direct or indirect competition across all of the common fundamentals between Tscan Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tscan Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tscan Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tscan Therapeutics to competition |
| Fundamentals | Tscan Therapeutics | Peer Average |
| Return On Equity | -0.65 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Operating Margin | (55.21) % | (5.51) % |
| Current Valuation | (94.26 M) | 16.62 B |
| Shares Outstanding | 52.31 M | 571.82 M |
| Shares Owned By Insiders | 0.82 % | 10.09 % |
| Shares Owned By Institutions | 90.50 % | 39.21 % |
| Number Of Shares Shorted | 2 M | 4.71 M |
| Price To Earning | 23.45 X | 28.72 X |
| Price To Book | 0.41 X | 9.51 X |
| Price To Sales | 34.97 X | 11.42 X |
| Revenue | 2.82 M | 9.43 B |
| Gross Profit | (2.03 M) | 27.38 B |
| EBITDA | (119.74 M) | 3.9 B |
| Net Income | (127.5 M) | 570.98 M |
| Cash And Equivalents | 125.6 M | 2.7 B |
| Cash Per Share | 5.22 X | 5.01 X |
| Total Debt | 65.31 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 7.53 X | 2.16 X |
| Book Value Per Share | 4.26 X | 1.93 K |
| Cash Flow From Operations | (110.82 M) | 971.22 M |
| Short Ratio | 5.80 X | 4.00 X |
| Earnings Per Share | (1.14) X | 3.12 X |
| Target Price | 9.71 | |
| Number Of Employees | 194 | 18.84 K |
| Beta | 0.91 | -0.15 |
| Market Capitalization | 98.47 M | 19.03 B |
| Total Asset | 371.12 M | 29.47 B |
| Retained Earnings | (375.1 M) | 9.33 B |
| Working Capital | 256.77 M | 1.48 B |
| Net Asset | 371.12 M |
Note: Acquisition by Baker Bros. Advisors Lp of 758094 shares of Tscan Therapeutics at 1.95 subject to Rule 16b-3 [view details]
Tscan Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tscan . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tscan Therapeutics Buy or Sell Advice
When is the right time to buy or sell Tscan Therapeutics? Buying financial instruments such as Tscan Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Tscan Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large & Mid Caps ETFs Thematic Idea Now
Large & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 69 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.